about
Annual burden of ocular toxoplasmosis in the US.Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2Toxoplasma gondii migration within and infection of human retina.Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence.Experimental Models of Ocular Infection with Toxoplasma Gondii.Parasitic infections and myositis.Therapy for ocular toxoplasmosis.Therapy for ocular toxoplasmosis--the future.Risk of Recurrence of Preexisting Ocular Toxoplasmosis during Pregnancy.Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii.Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis.Toxoplasmosis: new challenges for an old disease.
P2860
Q33693661-E75E2FD5-FF77-47AF-AA3B-2BBFCEEEB79CQ34271620-DED6D9DA-DFED-4BB8-AE6F-D31DDEFA2362Q34598064-1EA3C122-F0B6-4D9A-AF9E-C1045CF933FBQ35189546-B6AF766A-1C54-478F-AE49-10009EEE1A10Q36107947-C80469FC-810B-4CA8-BA5E-B6406F5D9D96Q36377328-5B3F1832-CBEE-452C-8F1B-C75E171A4E34Q37924643-D5B4148F-D661-466C-A448-E912BBA8793FQ37942263-C8EE91BC-549C-449F-9733-BAAF5C6AE9B5Q38101597-84846E0B-7A96-4C0C-B440-4DBD7E4FC5FCQ39189944-49BCCC3D-6746-423F-BFA4-57F02C8D5FCDQ40070106-851C4EB7-F22A-425A-9DEE-8B6428FCD5D6Q40749223-725C0801-6616-4EEB-AAFA-4D85467E85B0Q40847781-C1D8DC03-1095-4008-8288-F484C4D467EC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating ocular toxoplasmosis: current evidence.
@en
Treating ocular toxoplasmosis: current evidence.
@nl
type
label
Treating ocular toxoplasmosis: current evidence.
@en
Treating ocular toxoplasmosis: current evidence.
@nl
prefLabel
Treating ocular toxoplasmosis: current evidence.
@en
Treating ocular toxoplasmosis: current evidence.
@nl
P2860
P1476
Treating ocular toxoplasmosis: current evidence.
@en
P2093
Gilbert RE
Stanford MR
P2860
P304
P356
10.1590/S0074-02762009000200027
P577
2009-03-01T00:00:00Z